Promising new combo aims to shrink tumors faster in kids with tough hodgkin lymphoma
NCT ID NCT01920932
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether replacing a standard chemo drug with Adcetris (brentuximab vedotin) can improve early tumor shrinkage in children with high-risk Hodgkin lymphoma. About 77 participants will receive two cycles of the new combo, followed by more chemo and possibly radiation. The goal is to see if more kids achieve a complete response early, potentially reducing the need for radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin (Adcetris) plus chemotherapy (etoposide, prednisone, doxorubicin, cyclophosphamide, dacarbazine) and radiation therapy
What this could lead to
If successful, this approach could improve early cancer clearance and reduce the need for radiation in children with high-risk Hodgkin lymphoma.
What could go wrong
This is a small, early-phase trial (77 participants) with no control group. Results may not generalize, and side effects from the drug combination could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Harvard Cancer Center
Boston, Massachusetts, 02115, United States
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
Maine Children's Cancer Program (MCCP)
Scarborough, Maine, 04704, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
-
St. Jude Midwest Affiliate
Peoria, Illinois, 61637, United States